Literature DB >> 16637010

Proteomic analysis of the anterior cingulate cortex in the major psychiatric disorders: Evidence for disease-associated changes.

Clare L Beasley1, Kyla Pennington, Aine Behan, Robin Wait, Michael J Dunn, David Cotter.   

Abstract

Abnormalities of the anterior cingulate cortex have previously been described in schizophrenia, major depressive disorder and bipolar disorder. In this study 2-DE was performed followed by mass spectrometric sequencing to identify disease-specific protein changes within the anterior cingulate cortex in these psychiatric disorders. The 2-DE system comprised IPGs 4-7 and 6-9 in the first, IEF dimension and SDS-PAGE in the second dimension. Resultant protein spots were compared between control and disease groups. Statistical analysis indicated that 35 spots were differentially expressed in one or more groups. Proteins comprising 26 of these spots were identified by mass spectroscopy. These represented 19 distinct proteins; aconitate hydratase, malate dehydrogenase, fructose bisphosphate aldolase A, ATP synthase, succinyl CoA ketoacid transferase, carbonic anhydrase, alpha- and beta-tubulin, dihydropyrimidinase-related protein-1 and -2, neuronal protein 25, trypsin precursor, glutamate dehydrogenase, glutamine synthetase, sorcin, vacuolar ATPase, creatine kinase, albumin and guanine nucleotide binding protein beta subunit. All but three of these proteins have previously been associated with the major psychiatric disorders. These findings provide support for the view that cytoskeletal and mitochondrial dysfunction are important components of the neuropathology of the major psychiatric disorders.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16637010     DOI: 10.1002/pmic.200500069

Source DB:  PubMed          Journal:  Proteomics        ISSN: 1615-9853            Impact factor:   3.984


  97 in total

Review 1.  Collapsin response mediator proteins regulate neuronal development and plasticity by switching their phosphorylation status.

Authors:  Naoya Yamashita; Yoshio Goshima
Journal:  Mol Neurobiol       Date:  2012-02-18       Impact factor: 5.590

2.  Glial and glutamatergic markers in depression, alcoholism, and their comorbidity.

Authors:  José Javier Miguel-Hidalgo; Robert Waltzer; Angela A Whittom; Mark C Austin; Grazyna Rajkowska; Craig A Stockmeier
Journal:  J Affect Disord       Date:  2010-06-26       Impact factor: 4.839

3.  Proteome analyses of cultured astrocytes treated with MK-801 and clozapine: similarities with schizophrenia.

Authors:  Daniel Martins-de-Souza; Maria Lebar; Christoph W Turck
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2010-11-19       Impact factor: 5.270

Review 4.  New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates--Nrf2 activators and GSK-3 inhibitors.

Authors:  Michael Maes; Zdenĕk Fišar; Miguel Medina; Giovanni Scapagnini; Gabriel Nowak; Michael Berk
Journal:  Inflammopharmacology       Date:  2012-01-24       Impact factor: 4.473

Review 5.  Recent advances in neuroproteomics.

Authors:  Erika C Andrade; Dilja D Krueger; Angus C Nairn
Journal:  Curr Opin Mol Ther       Date:  2007-06

Review 6.  Gene expression in the etiology of schizophrenia.

Authors:  Nicholas J Bray
Journal:  Schizophr Bull       Date:  2008-03-11       Impact factor: 9.306

Review 7.  A mitochondrial bioenergetic basis of depression.

Authors:  N Jennifer Klinedinst; William T Regenold
Journal:  J Bioenerg Biomembr       Date:  2014-09-28       Impact factor: 2.945

Review 8.  Defects in Bioenergetic Coupling in Schizophrenia.

Authors:  Courtney R Sullivan; Sinead M O'Donovan; Robert E McCullumsmith; Amy Ramsey
Journal:  Biol Psychiatry       Date:  2017-10-24       Impact factor: 13.382

9.  Cortical expression of glial fibrillary acidic protein and glutamine synthetase is decreased in schizophrenia.

Authors:  Amy E Steffek; Robert E McCullumsmith; Vahram Haroutunian; James H Meador-Woodruff
Journal:  Schizophr Res       Date:  2008-06-17       Impact factor: 4.939

10.  Describing the hexapeptide identity platform between the influenza A H5N1 and Homo sapiens proteomes.

Authors:  Darja Kanduc
Journal:  Biologics       Date:  2010-09-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.